نمایش پرونده ساده آیتم

SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients

dc.contributor.authorMerat, S
dc.contributor.authorPoustchi, H
dc.contributor.authorSharifi, AH
dc.contributor.authorNateghi, A
dc.contributor.authorHajiani, E
dc.contributor.authorGharavi, A
dc.contributor.authorSomi, MH
dc.contributor.authorGhadir, MR
dc.contributor.authorKalantari, H
dc.contributor.authorMansour-Ghanaei, F
dc.contributor.authorKarimi, J
dc.contributor.authorFattahi, MR
dc.contributor.authorBaniasadi, N
dc.contributor.authorMoosavy, S
dc.contributor.authorDehghan-Manshadi, SA
dc.contributor.authorSofian, M
dc.contributor.authorSayad, B
dc.contributor.authorAbazar, P
dc.contributor.authorAmiriani, T
dc.contributor.authorBakhshipour, A
dc.contributor.authorMokhtare, M
dc.contributor.authorSharifian, A
dc.contributor.authorMinakari, M
dc.contributor.authorZahedi, MJ
dc.contributor.authorSohrabi, M
dc.contributor.authorGhezloo, M
dc.contributor.authorJamali, R
dc.contributor.authorToosi, SMV
dc.contributor.authorAfshar, B
dc.contributor.authorMaleki, I
dc.contributor.authorZiaee, M
dc.contributor.authorHormati, A
dc.contributor.authorSamani, FR
dc.contributor.authorEslami, L
dc.contributor.authorFakheri, H
dc.contributor.authorGoshayeshi, L
dc.contributor.authorSali, S
dc.contributor.authorSohrabpour, AA
dc.contributor.authorNorouzi, A
dc.contributor.authorSardarian, H
dc.contributor.authorJanbakhsh, A
dc.contributor.authorShayesteh, AA
dc.contributor.authorAhmadi, L
dc.contributor.authorMerat, D
dc.contributor.authorShayesteh, E
dc.contributor.authorMalekzadeh, R
dc.date.accessioned2018-08-26T06:35:51Z
dc.date.available2018-08-26T06:35:51Z
dc.date.issued2018
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/44274
dc.language.isoEnglish
dc.relation.ispartofJOURNAL OF VIRAL HEPATITIS
dc.relation.ispartof16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD)
dc.titleSD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients
dc.typeMeeting Abstract
dc.citation.volume25
dc.citation.spage198
dc.citation.epage199
dc.citation.indexWeb of science


فایلهای درون آیتم

فایلهاسایزفرمتنمایش

هیچ فایل مرتبطی وجود ندارد

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم